C. difficile

CRISPR Technology Edges Closer to Commercial Use
CRISPR Technology Edges Closer to Commercial Use
BioSpace
CRISPR
C. difficile
Flag link:
PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy
PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapy
Pharmaforum
Vedanta Biosciences
microbiome
C. difficile
BARDA
Flag link:
Battered and bruised Seres Therapeutics see shares skyrocket on phase 3 win
Battered and bruised Seres Therapeutics see shares skyrocket on phase 3 win
Fierce Biotech
Seres Therapeutics
SER-109
C. difficile
microbiome
Flag link:
In big year for microbiome drugs, a small biotech sets the bar
In big year for microbiome drugs, a small biotech sets the bar
BioPharma Dive
biotech
microbiome
Finch Therapeutics
C. difficile
Flag link:
Ferring’s gut microbiome drug clears phase 3 trial in C. diff
Ferring’s gut microbiome drug clears phase 3 trial in C. diff
Pharmaforum
Ferring Pharmaceuticals
clinical trials
microbiome
C. difficile
RBX2660
Flag link:
FDA Approves Merck's Dificid for Infections in Children
FDA Approves Merck's Dificid for Infections in Children
Motley Fool
FDA
Merck
Dificid
pediatric
C. difficile
Flag link:
MGB tops up cash pool to wrap up antibiotic phase 2a
MGB tops up cash pool to wrap up antibiotic phase 2a
Fierce Biotech
MGB Biopharma
antibiotics
MGB-BP-3
C. difficile
clinical trials
Flag link:
Microbiome company Finch raises $53M ahead of anti-infective readout
Microbiome company Finch raises $53M ahead of anti-infective readout
BioCentury
microbiome
Finch Therapeutics
C. difficile
Flag link:
Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering
Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering
CP Wire
Seres Therapeutics
C. difficile
ulcerative colitis
Flag link:
Microbiome-Focused Seres Therapeutics Inc. Announces Proposed Common Stock Offering
Seres Therapeutics
C. difficile
ulcerative colitis
Flag link:
Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile
Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile
CP Wire
Finch Therapeutics
CP101
C. difficile
microbiome
Flag link:
Investigational Live Microbial Drug Granted Breakthrough Therapy Designation for Recurrent C. Difficile
Finch Therapeutics
CP101
C. difficile
microbiome
Flag link:
Rebiotix to Report on Development of its Microbiome Health Index
Rebiotix to Report on Development of its Microbiome Health Index
CP Wire
Rebiotix
C. difficile
Flag link:
Rebiotix to Report on Development of its Microbiome Health Index
Rebiotix
C. difficile
Flag link:
Rebiotix to Present Data From First-In-Class Microbiota Restoration Therapy at IDWeek 2018
Rebiotix to Present Data From First-In-Class Microbiota Restoration Therapy at IDWeek 2018
CP Wire
Rebiotix
RBX2660
C. difficile
microbiome
Flag link:
Rebiotix to Present Data From First-In-Class Microbiota Restoration Therapy at IDWeek 2018
Rebiotix
RBX2660
C. difficile
microbiome
Flag link:
Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial
Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial
CP Wire
Summit Therapeutics
C. difficile
microbiome ridinilazole
Flag link:
J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout
J&J dumps a failed PhIII antibiotic program picked up in Actelion buyout
Endpoints
JNJ
Actelion
antibiotics
C. difficile
cadazolid
Flag link:
Pfizer, Valneva stand to gain from Sanofi's C. diff vaccine flop: report
Pfizer, Valneva stand to gain from Sanofi's C. diff vaccine flop: report
Fierce Pharma
Pfizer
Valneva
Sanofi
C. difficile
vaccines
PF-06425090
Flag link:
Sanofi’s bad, awful, terrible development week ends with PhIII C. diff failure
Sanofi’s bad, awful, terrible development week ends with PhIII C. diff failure
Endpoints
Sanofi
C. difficile
vaccines
clinical trials
Flag link:

Pages